FY2025 EPS Estimates for Genmab A/S Raised by HC Wainwright

Genmab A/S (NASDAQ:GMAB) – Equities researchers at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Genmab A/S in a research report issued on Thursday, April 24th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $1.58 per share for the year, up from their previous forecast of $1.48. HC Wainwright has a “Buy” rating and a $37.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2025 earnings at $0.47 EPS, Q1 2026 earnings at $0.29 EPS, Q2 2026 earnings at $0.53 EPS, Q3 2026 earnings at $0.51 EPS and Q4 2026 earnings at $0.52 EPS.

A number of other equities research analysts also recently weighed in on the company. Sanford C. Bernstein downgraded Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday, April 1st. Truist Financial decreased their price objective on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Finally, BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $39.17.

Genmab A/S Stock Performance

Genmab A/S stock opened at $20.79 on Monday. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $30.41. The firm’s fifty day moving average price is $20.41 and its 200-day moving average price is $21.00. The stock has a market cap of $13.76 billion, a P/E ratio of 11.95, a price-to-earnings-growth ratio of 2.65 and a beta of 1.07.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.

Institutional Trading of Genmab A/S

Institutional investors have recently modified their holdings of the company. AIMZ Investment Advisors LLC bought a new position in Genmab A/S during the 4th quarter valued at approximately $3,525,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Genmab A/S by 229.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company’s stock valued at $1,033,000 after acquiring an additional 34,652 shares in the last quarter. Blue Trust Inc. lifted its stake in Genmab A/S by 33.4% in the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock worth $120,000 after acquiring an additional 1,442 shares during the period. Raymond James Financial Inc. bought a new stake in Genmab A/S in the fourth quarter valued at $2,463,000. Finally, Sei Investments Co. increased its position in Genmab A/S by 55.2% during the 4th quarter. Sei Investments Co. now owns 57,702 shares of the company’s stock valued at $1,205,000 after purchasing an additional 20,525 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.